ME02594B - Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska - Google Patents

Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska

Info

Publication number
ME02594B
ME02594B MEP-2017-13A MEP1317A ME02594B ME 02594 B ME02594 B ME 02594B ME P1317 A MEP1317 A ME P1317A ME 02594 B ME02594 B ME 02594B
Authority
ME
Montenegro
Prior art keywords
combination
eye
subject
selective beta
dihydroxytetrahydrofuran
Prior art date
Application number
MEP-2017-13A
Other languages
German (de)
English (en)
French (fr)
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of ME02594B publication Critical patent/ME02594B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (9)

1.  Oftalmološka kombinacija koja obuhvata i) ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat, ili njegova farmaceutski prihvatljiva so, i ii) ne-selektivni beta-adrenergični receptor bloker odabran od timolola, levobunolola ili betaksolola, za upotrebu u snižavanju povišenog intraokularnog pritiska u oku subjekta.
2.  Kombinacija za upotrebu prema zahtevu 1, u kojoj ne-selektivni beta-adrenergični receptor bloker je timolol.
3.  Kombinacija za upotrebu prema bilo kom od zahteva 1 do 2, u kojoj se ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat nanosi na oko subjekta simultano, odvojeno ili sekvencijalno sa nanošenjem ne-selektivnog beta-adrenergičnog receptor blokera na oko subjekta.
4.  Kombinacija za upotrebu prema bilo kom od zahteva 1 do 3, u kojoj se oko 0,05 mg/ml do oko 7,0 mg/ml ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrata primenjuje na oko subjekta sa oko 1 do 2 kapi 2,5 mg/ml ne-selektivnog beta-adrenergičnog receptor blokera od 1 do 4 puta dnevno.
5.  Kombinacija za upotrebu prema zahtevu 4, u kojoj se oko 20-700µg, ili 20-350µg ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrata primenjuje na oko subjekta od 1 do 2 puta dnevno.
6.  Kombinacija za upotrebu prema bilo kom od zahteva 1 do 5, u kojoj se ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat i ne-selektivni beta-adrenergični receptor bloker daju topikalno na oko subjekta kao jedna ili više očnih kapi.
7.  Kombinacija za upotrebu prema bilo kom od zahteva 1 do 6 za upotrebu u tretiranju bolesti i stanja izazvanih povišenim intraokularnim pritiskom kod subjekta, u kojoj su bolesti i stanja izazvana povišenim intraokularnim pritiskom kod čoveka odabrana iz grupe koju čine očna hipertenzija, i primarni glaukom otvorenog ugla.
8.  Komplet koji obuhvata kombinaciju prema bilo kom od zahteva 1 do 7 za upotrebu u snižavanju povišenog intraokularnog pritiska u oku subjekta.
9.  Kombinacija koja obuhvata i) ((2R,3S,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat ili njegovu farmaceutski prihvatljivu so i ii) ne-selektivni beta-adrenergični receptor bloker odabran od timolola, levobunolola ili betaksolola, za upotrebu kao lek.
MEP-2017-13A 2010-03-19 2011-03-18 Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska ME02594B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31573110P 2010-03-19 2010-03-19
PCT/US2011/029012 WO2011116292A1 (en) 2010-03-19 2011-03-18 Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure
EP11757065.5A EP2555776B1 (en) 2010-03-19 2011-03-18 Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure

Publications (1)

Publication Number Publication Date
ME02594B true ME02594B (me) 2017-06-20

Family

ID=44649621

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-13A ME02594B (me) 2010-03-19 2011-03-18 Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska

Country Status (17)

Country Link
US (1) US8455457B2 (me)
EP (1) EP2555776B1 (me)
JP (1) JP2013522323A (me)
CN (1) CN102958526A (me)
CY (1) CY1118483T1 (me)
DK (1) DK2555776T3 (me)
ES (1) ES2613255T3 (me)
HR (1) HRP20170009T1 (me)
HU (1) HUE031530T2 (me)
LT (1) LT2555776T (me)
ME (1) ME02594B (me)
PL (1) PL2555776T3 (me)
PT (1) PT2555776T (me)
RS (1) RS55616B1 (me)
SI (1) SI2555776T1 (me)
SM (2) SMT201700020T1 (me)
WO (1) WO2011116292A1 (me)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596428A (en) * 2009-05-01 2014-03-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans
LT2523669T (lt) * 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
KR20150138182A (ko) * 2013-03-15 2015-12-09 이노텍 파마슈티컬스 코포레이션 안구 신경보호를 제공하는 방법
WO2016090005A1 (en) * 2014-12-03 2016-06-09 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
GB2436255B (en) * 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CN101010085B (zh) * 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
WO2009076580A2 (en) * 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
NZ596428A (en) * 2009-05-01 2014-03-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans

Also Published As

Publication number Publication date
EP2555776A4 (en) 2013-08-28
RS55616B1 (sr) 2017-06-30
US20110251151A1 (en) 2011-10-13
LT2555776T (lt) 2017-04-25
WO2011116292A1 (en) 2011-09-22
EP2555776B1 (en) 2016-12-07
CY1118483T1 (el) 2017-07-12
DK2555776T3 (en) 2017-02-06
HUE031530T2 (en) 2017-07-28
PL2555776T3 (pl) 2017-08-31
CN102958526A (zh) 2013-03-06
EP2555776A1 (en) 2013-02-13
SMT201700020B (it) 2017-03-08
ES2613255T3 (es) 2017-05-23
SMT201700020T1 (it) 2017-03-08
PT2555776T (pt) 2017-02-01
SI2555776T1 (sl) 2017-05-31
JP2013522323A (ja) 2013-06-13
HRP20170009T1 (hr) 2017-03-10
US8455457B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
ME02594B (me) Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
ME02608B (me) Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
HRP20151200T1 (hr) Metoda za snižavanje intraokularnog tlaka kod ljudi
RU2012103538A (ru) Композиции и способы ингибирования пути jak
KR102496934B1 (ko) 안과용 제제
Kim et al. In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
HRP20170502T1 (hr) Antagonisti cb 1 receptora
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
Aptel et al. Intraocular pressure-lowering combination therapies with prostaglandin analogues
Pfeiffer et al. Neuroprotection of medical IOP-lowering therapy
ES2921360T3 (es) Compuestos para el tratamiento de enfermedades oculares asociadas a una vascularización excesiva
DK2598118T3 (en) CONSERVATIVE-FREE BIMATOPROST AND TIMOLOL SOLUTIONS
ME02593B (me) Kombinovane kompozicije adenozinskih a1 agonista i inhibitora ugljene anhidraze za snižavanje intraokularnog pritiska
IL274234B2 (en) Compositions and methods for the treatment of eye disorders
JP2014506927A5 (me)
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
MX2009003750A (es) Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
WO2009022897A3 (es) Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal
CA3073718A1 (en) Ocular pharmaceutical compositions
KR20200088824A (ko) 근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
WO2012125400A1 (en) Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases